08/17/2026
A Pancreatic Cancer Breakthrough Shows What Innovation Can Deliver
For decades, metastatic pancreatic cancer has remained among the most difficult cancers to treat. At the 2026 American Society of Clinical Oncology Annual Meeting (https://www.asco.org/abstracts-presentations/268016), researchers presented findings that brought the audience to its feet.
In the phase 3 RASolute 302 trial, the investigational medicine daraxonrasib doubled median overall survival among patients with previously treated metastatic pancreatic cancer, from approximately 6.7 months with chemotherapy to 13.2 months. It also reduced the risk of death by 60%, extended progression-free survival and delayed deterioration in pain and quality of life. Read more about the results: https://www.oncologynewscentral.com/pancreatic-cancer/standing-ovation-at-asco-2026-for-grand-slam-pancreatic-cancer-data-daraxonrasib-doubles-survival
Daraxonrasib is not yet approved by the FDA, but these findings demonstrate what sustained scientific research, private investment and rigorous clinical trials can make possible. For patients and families, additional months are far more than a statistic. They mean more time together and renewed hope against a disease that has offered too little of either.
Virginia has a direct stake in protecting this innovation ecosystem. The Commonwealth is home to more than 3,400 life sciences companies, an industry that supports more than 30,000 jobs, contributes approximately $8 billion to Virginia’s economy and sponsors nearly 1,200 clinical trials each year. Pro-innovation policies can help Virginia attract capital, develop scientific talent, expand advanced manufacturing and move discoveries from the laboratory to patients.
As policymakers debate Most-Favored-Nation pricing and potential expansions of federal drug-price controls, they must consider how those decisions could affect investment in the next generation of treatments. Patients need affordable access to today’s medicines, but they also need the breakthroughs still being developed.
Virginia Bio supports policies that advance both access and innovation, strengthen Virginia’s growing biotechnology sector and ensure researchers can continue pursuing treatments once thought beyond reach.
